Outset Medical Inc is committed to revolutionizing the delivery of kidney dialysis by providing a patient-centric approach. The company's corporate philosophy revolves around their core values of innovation, efficiency, and compassion. Outset Medical aims to improve the overall patient experience by developing innovative technology and solutions that simplify and streamline dialysis treatment. They prioritize cost-effectiveness and accessibility for patients and healthcare providers. With a focus on patient empowerment and convenience, Outset Medical Inc strives to redefine the standards of kidney care, ensuring better outcomes and enhancing the quality of life for individuals living with kidney disease.

Outset Medical Inc is primarily present in the United States.

Outset Medical Inc, a leading medical technology company, has achieved several significant milestones. Firstly, the company successfully developed the Tablo Hemodialysis System, a groundbreaking solution for patients requiring kidney dialysis. Tablo offers portability and simplicity, enhancing patient access and care. Secondly, Outset Medical received regulatory approval from the U.S. Food and Drug Administration (FDA) in 2015 and launched Tablo commercially in 2017. This marked a major achievement for the company, enabling widespread adoption of their innovative system. Furthermore, Outset Medical has secured substantial funding, raising over $500 million in its initial public offering (IPO) in September 2020. These achievements highlight the exceptional progress made by Outset Medical Inc in revolutionizing dialysis treatment.

Outset Medical Inc. is a medical technology company that specializes in kidney care innovation. The company was founded in 2003 and is headquartered in San Jose, California. Outset Medical is known for developing the Tablo Hemodialysis System, a portable and user-friendly device that simplifies and enhances the dialysis treatment experience. The Tablo system integrates all the necessary components into a single, compact platform, providing flexibility and convenience for patients and healthcare providers. With its advanced technology and vision to transform the dialysis market, Outset Medical Inc. is committed to improving the lives of kidney disease patients worldwide.

The main competitors of Outset Medical Inc in the market include Becton, Dickinson and Company (BD), NxStage Medical Inc, and Fresenius Medical Care AG & Co. KGaA.

Outset Medical Inc is primarily active in the healthcare industry.

The business model of Outset Medical Inc revolves around providing innovative medical technology solutions. As a leading medical technology company, Outset Medical Inc focuses on the development and commercialization of disruptive hemodialysis systems. Their flagship product, the Tablo Hemodialysis System, offers an all-in-one platform that enhances patient experience, reduces costs, and improves clinical outcomes. Outset Medical Inc's business model is designed to address the unmet needs of patients, providers, and payers, aiming to revolutionize the field of kidney care. Through their advanced technology and comprehensive approach, the company aims to improve the quality of life for individuals suffering from kidney diseases.

Outset Medical KGV ir -0,26.

Outset Medical KUV ir 0,23.

AlleAktien kvalitātes vērtējums Outset Medical ir 3/10.

gaidāmā Outset Medical apgrozījums ir 113,53 milj. USD.

gaidāmā Outset Medical peļņa ir -99,08 milj. USD.

Outset Medical Inc. is an American company that operates in the healthcare sector and has developed advanced technology for dialysis treatment. The company offers a complete range of products for safe, simple, and intuitive dialysis treatment for patients and medical professionals. Outset Medical Inc.'s business model is based on the idea of revolutionizing dialysis treatment and automating and simplifying the process. The core idea is the development of a medical device called Tablo, which is capable of taking over all steps of the dialysis treatment from preparation to procedure execution. The company aims for a comprehensive solution that extends from device development to maintenance and the purchase of consumables. With this approach, Outset Medical Inc. achieves the goal of providing a comprehensive solution for dialysis treatment that takes into account the needs of both patients and medical facilities. The central product of Outset Medical Inc. is the Tablo system, an innovative technology that has the potential to fundamentally change the dialysis market. It is a portable dialysis machine that automatically performs all steps of the treatment, including device cleaning and disinfection. The Tablo system is designed to be intuitive and user-friendly, allowing medical professionals to perform dialysis treatment without specialized training. It is also a safe option for patients, as the device is fully sterilized and capable of preventing infections. In addition to the Tablo system, Outset Medical Inc. also offers a wide range of consumables such as dialysis filters, exchangers, and catheters. These consumables are manufactured to the highest quality standards and are designed to achieve optimal results in conjunction with the Tablo system. Furthermore, the company provides comprehensive training and support for the medical professionals using the Tablo system in their facility. Trained technicians offer training for the medical staff to ensure that the device is used safely and effectively. Overall, Outset Medical Inc.'s business model is focused on providing a complete solution for dialysis treatment that is safe, simple, and intuitive. With their innovative technology and wide range of products and services, the company offers a comprehensive solution for the ever-evolving needs of the dialysis market.

Outset Medical izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Outset Medical vai uzņēmums nedod dividendes.

Outset Medical ISIN ir US6901451079.

Outset Medical WKN ir A2QB2U.

Outset Medical simbols ir OM.

Pēdējo 12 mēnešu laikā Outset Medical maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Outset Medical plāno maksāt dividendes 0 USD apmērā.

Outset Medical pašreizējā dividendu rentabilitāte ir .

Outset Medical maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Outset Medical pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Outset Medical tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Outset Medical apmērā 0 USD, kas tika izmaksāta 17.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 17.09.2024..

Pēdējās dividendes izmaksa notika 17.09.2024..

Gadā 2023, Outset Medical izmaksāja 0 USD dividendes.

Outset Medical dividendes tiek izmaksātas USD.